CORT has been successfully added to your Stock Email Alerts list.
You can manage your stock email alerts here.
CORT has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
EPS Growth Rate (Future 3Y To 5Y Estimate) is the average growth rate of earnings per share (EPS) estimates over a 3-year to 5-year period.
As of today, Corcept Therapeutics's EPS Growth Rate (Future 3Y To 5Y Estimate) is N/A.
For the Biotechnology subindustry, Corcept Therapeutics's EPS Growth Rate (Future 3Y To 5Y Estimate), along with its competitors' market caps and EPS Growth Rate (Future 3Y To 5Y Estimate) data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
For the Biotechnology industry and Healthcare sector, Corcept Therapeutics's EPS Growth Rate (Future 3Y To 5Y Estimate) distribution charts can be found below:
* The bar in red indicates where Corcept Therapeutics's EPS Growth Rate (Future 3Y To 5Y Estimate) falls into.
Corcept Therapeutics (NAS:CORT) EPS Growth Rate (Future 3Y To 5Y Estimate) Explanation
EPS Growth Rate (Future 3Y To 5Y Estimate) s the average growth rate of earnings per share (EPS) estimates over a 3-year to 5-year period.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average earnings per share (EPS) estimates growth rate.
Thank you for viewing the detailed overview of Corcept Therapeutics's EPS Growth Rate (Future 3Y To 5Y Estimate) provided by GuruFocus.com. Please click on the following links to see related term pages.
Swisher Daniel N Jr | director | C/O SUNESIS PHARMACEUTICALS, INC., 395 OYSTER POINT BLVD., SUITE 400, SOUTH SAN FRANCISCO CA 94080 |
William Guyer | officer: Chief Development Officer | C/O CORCEPT THERAPEUTICS INCORPORATED, 149 COMMONWEALTH DRIVE, MENLO PARK CA 94025 |
Gary Charles Robb | officer: CHIEF FINANCIAL OFFICER | C/O 149 COMMONWEALTH DRIVE, MENLO PARK CA 94025 |
Joseph Douglas Lyon | officer: Chief Accounting Officer | C/O CORCEPT THERAPEUTICS INCORPORATED, 149 COMMONWEALTH DRIVE, MENLO PARK CA 94025 |
Sean Maduck | officer: See Remarks | C/O CORCEPT THERAPEUTICS INCORPORATED, 149 COMMONWEALTH DRIVE, MENLO PARK CA 94025 |
David L Mahoney | director | SYMANTEC CORPORATION, 20330 STEVENS CREEK BLVD., CUPERTINO CA 95014 |
Hazel Hunt | officer: Chief Scientific Officer | C/O CORCEPT THERAPEUTICS INCORPORATED, 149 COMMONWEALTH DRIVE, MENLO PARK CA 94025 |
Joseph K Belanoff | director, officer: CHIEF EXECUTIVE OFFICER | 149 COMMONWEALTH DRIVE, MENLO PARK CA 94025 |
Baker G Leonard Jr | director, 10 percent owner | 755 PAGE MILL ROAD, SUITE A-200, PALO ALTO CA 94304-1005 |
Joshua M. Murray | director | C/O CORCEPT THERAPEUTICS INCORPORATED, 149 COMMONWEALTH DRIVE, MENLO PARK CA 94025 |
Atabak Mokari | officer: Chief Financial Officer | 1212 TERRA BELLA AVENUE, MOUNTAIN VIEW CA 94043 |
Gillian Cannon | director | C/O CORCEPT THERAPEUTICS INCORPORATED, 149 COMMONWEALTH DRIVE, MENLO PARK CA 94025 |
Gregg H Alton | director | 333 LAKESIDE DRIVE, FOSTER CITY CA 94404 |
Kimberly Park | director | C/O CORCEPT THERAPEUTICS INCORPORATED, 149 COMMONWEALTH DRIVE, MENLO PARK CA 94025 |
Andreas Grauer | officer: Chief Medical Officer | C/O CORCEPT THERAPEUTICS INCORPORATED, 149 COMMONWEALTH DRIVE, MENLO PARK CA 94025 |
From GuruFocus
By sperokesalga sperokesalga • 02-13-2023
By GuruFocus Research • 09-07-2023
By Marketwired • 08-02-2023
By Marketwired • 10-26-2023
By PurpleRose PurpleRose • 08-06-2022
By sperokesalga sperokesalga • 04-26-2023
By Marketwired • 11-01-2023
By GuruFocusNews GuruFocusNews • 07-09-2022
By GuruFocus Research • 09-07-2023
Disclaimers: GuruFocus.com is not operated by a broker or a dealer. It has an affiliated registered investment adviser, which serves as the subadviser to an exchange traded fund. This investment adviser does not provide advice to individual investors. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes provided by InterActive Data. Fundamental company data provided by Morningstar, updated daily.